ABION Inc. (KOSDAQ:203400)

Market Cap	224.80B +28.5%
Revenue (ttm)	880.14M +15.9%
Net Income	-29.06B
EPS	-434.00
Shares Out	90.10M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	525,834
Average Volume	594,613
Open	2,585.00
Previous Close	2,550.00
Day's Range	2,480.00 - 2,615.00
52-Week Range	1,911.11 - 7,277.78
Beta	1.17
RSI	44.46
Earnings Date	Apr 30, 2026

About ABION

ABION Inc. operates as a pharmaceutical biotech Company in South Korea and internationally. The company develops anticancer therapeutic drugs, such as ABN401, a tyrosine kinase inhibitor that is in Phase II clinical trials for treating non-small cell lung cancer, as well as in Phase I clinical trial for breast cancer; ABN501, a human monoclonal antibody that targets claudin 3 for treating solid cancers; ABN201, an antibody cytokine fusion protein to treat solid cancers; and ABN101, a dry powder inhaler as a prophylactic treatment for various re...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2007
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 203400

Financial Performance

In 2025, ABION's revenue was 880.14 million, an increase of 15.86% compared to the previous year's 759.68 million. Losses were -29.06 billion, -33.00% less than in 2024.